61MO IMscin001 (part 2: randomized phase III): Pharmacokinetics (PK), efficacy and safety of atezolizumab (atezo) subcutaneous (SC) vs intravenous (IV) in previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC)

Autor:	M. Burotto, Z. Zvirbule, A. Mochalova, Y. Runglodvatana, L.A. Herraez Baranda, S. Liu, P. Chan, E. Shearer-Kang, M. Shivhare, N. Tosti, J. Zanghi, B. Leutgeb, E. Felip
Rok vydání:	2022
Předmět:	Oncology Immunology and Allergy
Zdroj:	Immuno-Oncology and Technology. 16:100166
ISSN:	2590-0188
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::b577f33698ee21291ed35777badc530a https://doi.org/10.1016/j.iotech.2022.100166 Zobrazit plný text záznamu